Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 2, 100045
Abstract
No abstract availableKeywords
Funding Information
- NIAID (P30-AI-050409, R01-AI-121315, R01-AI-141327)
- National Institutes of Health
This publication has 40 references indexed in Scilit:
- Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and ManagementClinical Gastroenterology and Hepatology, 2020
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceScience Translational Medicine, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- WHO Declares COVID-19 a Pandemic2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Intracellular metabolism and potential cardiotoxicity of a β-D-2’-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replicationNucleosides, Nucleotides & Nucleic Acids, 2019
- Cell-line dependent antiviral activity of sofosbuvir against Zika virusAntiviral Research, 2017
- Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter GeneAntimicrobial Agents and Chemotherapy, 2016
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Intracellular Metabolism of Nucleoside/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse TranscriptaseCurrent Drug Metabolism, 2016